SHYFT Analytics, a Medidata Solutions, today announced that Novartis has selected its Intelligent Platform for Life Sciences to support the commercialization of key therapies in Europe. As part of the collaboration, Novartis will use the following SHYFT solutions:
– STRATA Data Platform to aggregate and manage a growing number of third party and proprietary commercial data sources
– LUMEN Insights Platform to deliver intuitively-designed analytics to drive the “next-best-actions” for commercial teams
Together, these solutions simplify and accelerate the aggregation, assimilation, and analysis of scores of disparate data sets that inform commercial sales and medical education programs.
In addition, Novartis’ new partnership with SHYFT extends its existing collaboration with Medidata in support of its clinical trials and commercialization programs. Medidata and SHYFT provide the Intelligent Platform for Life Sciences, an end-to-end data and analytics solution that empowers life sciences organizations to close the loop between clinical and commercial insights and accelerate their digital transformation.
SHYFT’s data analytics platform is the most efficient and scalable way to transform massive amounts of complex healthcare data into on-demand clinical and commercial insight.
“Pharma companies are acutely aware of the tremendous demands on healthcare professionals’ time. Every minute is important, and every interaction we have with a healthcare professional must be efficient, relevant, and impactful,” said Bertrand Bodson, Chief Digital Officer at Novartis. “Medidata and SHYFT have come together in a way that allows us to share data and insights seamlessly across our Clinical Development and Commercial teams. We are committed to reimagining medicine with data and digital, and this technology helps us do that by supporting our pharma sales reps with intelligence-driven ‘next-best-actions’ so they can make the 100,000 interactions they have with HCPs every day as personalized and meaningful as possible.”